Source briefingSeptember 9, 2026Health & Science
Multimodal protective and susceptibility clusters in paediatric atopic dermatitis: A machine learning-based, data-driven observational study

Source briefing · A concise briefing based on one linked source. It is intentionally shorter than a full FreedomWitness Evidence Engine analysis.
What the source reports
by Damir Zhakparov, Nonhlanhla Lunjani, Marco Schmid, Kathleen Moriarty, Damian Roquero, Anita Dreher, Jeannette I. Heldstab-Kast, Kari C. Nadeau, Cezmi Akdis, Michael Levin, Carol Hlela, Milena Sokolowska, Liam O’Mahony, Katja Baerenfaller Background Atopic dermatitis (AD) is a chronic inflammatory skin disease that typically develops in early childhood.
Differences in AD prevalence and allergy sensitisation patterns have been observed in African populations, including the AmaXhosa population in South Africa, suggesting alternative pathogenic and immune mechanisms underlying AD. Differences in AD prevalence have also…
Evidence note: At this stage FreedomWitness is presenting what this source reports. This briefing does not independently prove every underlying claim and should be read together with the original material.
Source & verification
Primary source: PLOS Medicine · September 8, 2026
FreedomWitness links to the original source so readers can inspect the underlying material and judge the context for themselves.
Continue reading

US Tries but Fails to Dilute UN Human Rights Resolutions
US Attempts to Weaken UN Human Rights Resolutions: An Evidence Review What is established In late 2026, during sessions of the United Nations General…

Medical device makers have gotten worse at disclosing when their products harm people, new study finds. The FDA let them.
What is established A recent peer-reviewed study published in The BMJ and reported by the International Consortium of Investigative Journalists (ICIJ) reveals a decline…

EMA/PE/0000181364
What is established The European Medicines Agency (EMA) has granted a decision regarding a paediatric investigation plan (PIP) for vosoritide as of 8 August…